CA2569100A1 - Procede d'identification du risque de cancer du sein et traitement de celui-ci - Google Patents

Procede d'identification du risque de cancer du sein et traitement de celui-ci Download PDF

Info

Publication number
CA2569100A1
CA2569100A1 CA002569100A CA2569100A CA2569100A1 CA 2569100 A1 CA2569100 A1 CA 2569100A1 CA 002569100 A CA002569100 A CA 002569100A CA 2569100 A CA2569100 A CA 2569100A CA 2569100 A1 CA2569100 A1 CA 2569100A1
Authority
CA
Canada
Prior art keywords
seq
nucleotide sequence
breast cancer
polymorphic
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002569100A
Other languages
English (en)
Inventor
Richard B. Roth
Matthew Roberts Nelson
Andreas Braun
Stefan M. Kammerer
Rikard Reneland
Caridad Rosette
Mikhail F. Denissenko
Jonas Goeran Ekblom
Carolyn R. Hoyal-Wrightson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Sequenom Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sequenom Inc filed Critical Sequenom Inc
Publication of CA2569100A1 publication Critical patent/CA2569100A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA002569100A 2004-05-27 2004-05-27 Procede d'identification du risque de cancer du sein et traitement de celui-ci Abandoned CA2569100A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2004/016940 WO2005118834A2 (fr) 2004-05-27 2004-05-27 Procede d'identification du risque de cancer du sein et traitement de celui-ci

Publications (1)

Publication Number Publication Date
CA2569100A1 true CA2569100A1 (fr) 2005-12-15

Family

ID=35463458

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002569100A Abandoned CA2569100A1 (fr) 2004-05-27 2004-05-27 Procede d'identification du risque de cancer du sein et traitement de celui-ci

Country Status (3)

Country Link
EP (1) EP1766041A2 (fr)
CA (1) CA2569100A1 (fr)
WO (1) WO2005118834A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1734118A1 (fr) * 2005-06-15 2006-12-20 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Identification de gènes modulateurs de la voie de signalisation JAK/STAT par criblage du génome à l'aide d'ARNi
WO2016094802A1 (fr) * 2014-12-11 2016-06-16 Worcester Polytechnic Institute Caractérisation d'un biomarqueur de pré-cancer pour un dépistage pronostique
WO2018132662A1 (fr) * 2017-01-14 2018-07-19 Nutech Ventures Protéase mitochondriale oma1 utilisée en tant que marqueur du cancer du sein

Also Published As

Publication number Publication date
WO2005118834A2 (fr) 2005-12-15
WO2005118834A3 (fr) 2007-09-13
EP1766041A2 (fr) 2007-03-28

Similar Documents

Publication Publication Date Title
DK2456889T3 (en) Markers of endometrial cancer
US6773883B2 (en) Prognostic classification of endometrial cancer
US20090317816A1 (en) Methods for identifying risk of breast cancer and treatments thereof
US20030068636A1 (en) Compositions, kits and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer
US20090305284A1 (en) Methods for Identifying Risk of Breast Cancer and Treatments Thereof
AU2014373927B2 (en) Prostate cancer gene profiles and methods of using the same
US20040219579A1 (en) Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US20050170500A1 (en) Methods for identifying risk of melanoma and treatments thereof
US20050277118A1 (en) Methods for identifying subjects at risk of melanoma and treatments thereof
US20080199480A1 (en) Methods for Identifying Risk of Type II Diabetes and Treatments Thereof
US20050064442A1 (en) Methods for identifying risk of breast cancer and treatments thereof
WO2006022633A1 (fr) Methodes d'identification de risque de diabete de type ii et traitements associes
CA2569100A1 (fr) Procede d'identification du risque de cancer du sein et traitement de celui-ci
US20090258344A1 (en) Methods for identifying risk of breast cancer and treatments thereof
US20020155119A1 (en) Isolation and use of fetal urogenital sinus expressed sequences
US20050118606A1 (en) Methods for identifying risk of breast cancer and treatments thereof
EP2112229A2 (fr) Procédés d'identification du risque du cancer du sein et traitements associés

Legal Events

Date Code Title Description
FZDE Discontinued